Pediatric spontaneous-reporting patterns for biologics approved or used for asthma: Analysis of the FDA adverse event reporting system.

Xolair (omalizumab) - Roche, Novartis

Tezspire (tezepelumab-ekko) - AstraZeneca, Amgen

Nucala (mepolizumab) - GSK

Fasenra (benralizumab) - AstraZeneca

Dupixent (dupilumab) - Sanofi, Regeneron

http://www.ncbi.nlm.nih.gov/pubmed/42748074

Lingli Chen; Xiangrong Zheng; Yating Chen; Yile Liu; Yue Zhang

Sep 17, 2026